Astellas Pharma

Astellas Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Astellas Pharma (4503.T) as of Nov 4, 2026 is 174.43 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 324.37 % — a change of -46.23% (lower).

FCF Conversion

174.43 %

YoY

-46.23%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Astellas Pharma is 2026 174.43 % . FCF Conversion Rate (FCF/EBITDA) of Astellas Pharma was 2025 324.37 % . It decreases by -46.23% lower compared to the previous year.

The Astellas Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
106.29 JPY
Jan 1, 2020
73.75 JPY
Jan 1, 2021
190.23 JPY
Jan 1, 2022
145.86 JPY
Jan 1, 2023
242.34 JPY
Jan 1, 2024
840.53 JPY
Jan 1, 2025
324.37 JPY
Jan 1, 2026
174.43 JPY
The Astellas Pharma FCF Conversion history
YEARFCF ConversionYoY
174.43 %-46.23%
324.37 %-61.41%
840.53 %+246.84%
242.34 %+66.14%
145.86 %-23.32%
190.23 %+157.96%
73.75 %-30.61%
106.29 %-39.52%
175.73 %+84.57%
95.21 %-34.84%
146.12 %+19.72%
122.05 %-41.10%
207.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Astellas Pharma Stock analysis

What does Astellas Pharma do? Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Astellas Pharma stock

FCF Conversion Rate (FCF/EBITDA) of Astellas Pharma is 174.43 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Astellas Pharma changed from 324.37 % to 174.43 %, representing a -46.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Astellas Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Astellas Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Astellas Pharma

All Key Metrics — Astellas Pharma